维普中文期刊产品整合服务
12篇 您的检索式:作者名="MARREM"
    题名 作者 年代 出处 被引量
1GP73,a resident Golgi glycoprotein,is a novel serum marker for hepatocellular carcinoma显示文摘Marrem JA Romano PR Nikoheva O 0,,06:1
2Anaerobic growth pro- motes synthesis of colonization factors encoded at the Vibrio pathoge- nicity island in Vibrio cholerae E1Tor显示文摘Marrem K Sanchez A Redriguez-ulloa A 2009Res Mierobiol2009,160,1:1
3The respiratory burst and electrolyte leakage induced by sulfhydryl blockers in egria densa leaves are assoceated with H2O2 production and are dependent with on Ca^2+ influx显示文摘MARREM T AMICUCCI E ZINGARELLI L 1998Plant Physiol1998,118,:1
4GP73, a res ident Golgi glycoprotein, is a novel serum marker for hepato- cellular earciaoma 显示文摘Marrem JA Romano PR Nikoheva () etal 2005Hepatol2005,43,6:1
5Liraglutide, aonce-dai-ly human GLP-1 analogue,added to a sulphonylurea over 26 weeksproduces grealer improvements in glycaemic and weight control eom-pared with adding rosiglitazone or placebo in subjects with Type 2 di-abetes (LEAD- 1 SU )显示文摘MARREM SHAW J BRANDLEM 2009Diabetic Medicine2009,26,3:1
6GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma显示文摘Marrem JA Romano PR Nikoheva 0 2005J Hepatol2005,43,6:1
7Tissular toxicity of glucose and therapeuticperspectives显示文摘Larger E MarreM 2001Rev Prat2001,51,16:1
8Effect of vitamin E and C dietary supplementation on some immune parameters of gihhead seabream (Sparus aurata) juveniles subjected to crowding stress 显示文摘MONTEM D MARREM M IZQUIERDO M S 1999Aq- uaculture1999,171,:1
9GP73, a resident Golgi glycoproteln, is a novel serum marker for hepatocellular carcinoma 显示文摘Marrem J A Romano P R Nikolaeva O 2005J Hepatol2005,43,6:1
10Diagnosis and treatment of hepatocellular carcinoma显示文摘E1-Serag HB Marrem JA Rudolph L 2008Gastroenterology2008,134,6:1
11GP73, a residenl golgi glycoprotein is a novel serum marker for hepatoeeUular carcinoma 显示文摘Marrem JA Romano PR Nikolaeva O 2005J Hepatol2005,43,6:1
12最佳方式的胰岛素aspart和人胰岛素注射对1型糖尿病人血糖控制的作用——一项随机多国研究显示文摘胰岛素aspart(IAsp),是一种速效的人胰岛素(HI)类似物,用于糖尿病人餐时的血糖控制,在为期3个月的实验中以algorithm-driven调整剂量,比较IAsp和HI的血糖控制情况,这是一个前瞻性,多中心,随机,开放性,平行对照研究,包括11个国家的48个中心,423名基础-餐前冲击治疗的1型糖尿病人参加,主要的评价指标是血糖控制情况,包括HbA1c,9个测定时点自我监测血糖波动图,胰岛素剂量,生活质量,低血糖和不良事件,每天基础胰岛一纱注射的剂量和次数按Algo-rithm-driven增加,特别是在IAsp组,治疗12周后IAsp组比HI组HbA1c显著降低0.17(95%CI0.30-0.40;P<0.05)。比较两组血糖情况,可见IAsp组早餐后血糖(8.4vs10.1mmol/L;P<0.0001)和晚餐后血糖(8.2vs9.3mmol/L;P<0.01)比HI组低,低血糖事件和不良事件在两组差异无显著性,WHO糖尿病治疗满意度调查问卷显示IAsp组可觉察的高血糖计分低于HI组(P=0.005)。并且病人发现IAsp治疗更灵敏(P=0.022)。本研究提示基础胰岛素的给予尚需完整,才能充分发挥IAsp药效学优点。TamasGY MarreM 等 2002中华内分泌代谢杂志2002,18,6:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费